Orfit Industries Revenue and Competitors
Estimated Revenue & Valuation
- Orfit Industries's estimated annual revenue is currently $22.1M per year.
- Orfit Industries's estimated revenue per employee is $251,000
Employee Data
- Orfit Industries has 88 Employees.
- Orfit Industries grew their employee count by 11% last year.
Orfit Industries Competitors & Alternatives
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $19.1M | 76 | -7% | N/A | N/A |
#2 | $22.1M | 88 | -8% | N/A | N/A |
#3 | $49.9M | 199 | N/A | N/A | N/A |
#4 | $275.3M | 1097 | 7% | N/A | N/A |
#5 | $59.7M | 238 | N/A | N/A | N/A |
#6 | $62.5M | 249 | -10% | N/A | N/A |
#7 | $36.4M | 145 | -2% | N/A | N/A |
#8 | $45.4M | 181 | -3% | N/A | N/A |
#9 | $100.7M | 401 | N/A | N/A | N/A |
#10 | $209.3M | 834 | N/A | N/A | N/A |
What Is Orfit Industries?
Based on innovative technologies, Orfit develops and produces the most precise and reliable thermoplastic materials for medical devices that improve patient treatment around the world. The Orfit team provides immobilization systems for cancer patients in Radiation Oncology; orthotic fabrication materials for patients in Physical Rehabilitation and prosthetic socket materials for amputee patients. Our core expertise is the development and the production of thermoplastic materials with specific properties for reliable, safe and comfortable immobilization and mobilization. Active in Radiation Oncology? Join the Orfit Radiation Oncology Group: http://www.linkedin.com/groups/Orfit-Radiation-Oncology-Group-7430333/about Immobilization systems for cancer patients in Radiation Oncology, Prosthetic socket materials for amputee patients, Orthotic fabrication materials for patients in Physical Rehabilitation
keywords:N/AN/A
Total Funding
88
Number of Employees
$22.1M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 102 | -1% | N/A |